Scienture Holdings, Inc.
$ 0.34
-1.75%
14 Apr - close price
- Market Cap 13,936,400 USD
- Current Price $ 0.34
- High / Low $ 0.37 / 0.34
- Stock P/E N/A
- Book Value 1.73
- EPS -2.70
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.56 %
- 52 Week High 2.60
- 52 Week Low 0.24
About
Scienture Holdings, Inc. (SCNX) is an innovative biotechnology company focused on developing cutting-edge therapeutic solutions for neurological disorders. With a robust drug development pipeline supported by advanced technology and a highly skilled research team, Scienture is committed to meeting unmet medical needs and improving patient outcomes. The company's strategic emphasis on scientific excellence, regulatory compliance, and collaborative partnerships positions it well for growth within the burgeoning healthcare sector, highlighting its potential to make significant contributions to global health advancements.
Analyst Target Price
$1.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-30 | 2025-11-12 | 2025-08-12 | 2025-04-21 | 2025-03-26 | 2024-11-29 | 2024-07-22 | 2024-04-24 | 2024-03-25 | 2023-10-25 | 2023-07-24 | 2023-05-15 |
| Reported EPS | -0.13 | -0.19 | -0.48 | -0.3251 | -0.79 | -1.3411 | -1.304 | 20.4928 | -12.9457 | -4.571 | -2.8991 | -0.07 |
| Estimated EPS | -0.28 | 0 | None | None | 0.38 | None | None | None | None | None | -0.45 | -0.02 |
| Surprise | 0.15 | -0.19 | 0 | 0 | -1.17 | 0 | 0 | 0 | 0 | 0 | -2.4491 | -0.05 |
| Surprise Percentage | 53.5714% | None% | None% | None% | -307.8947% | None% | None% | None% | None% | None% | -544.2444% | -250% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jul 2024 | Mar 2024 | |
|---|---|---|
| Payment Date | 2024-07-24 | 2024-03-22 |
| Amount | $1.5 | $8.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCNX
2026-04-07 07:10:34
Scienture Holdings, Inc. announced significant progress in its annual shareholder update, highlighting the successful FDA approval and commercial launch of Arbli™ for hypertension and the upcoming launch of REZENOPY™ for opioid overdose. The company reported a 216% increase in net revenue for 2025, driven by Arbli's initial market traction, and outlined its R&D pipeline and strategic priorities for 2026, including maximizing commercial performance and advancing pipeline candidates. Scienture also addressed its Nasdaq compliance status, indicating its intention to request an extension if needed.
2026-04-06 21:40:03
Scienture Holdings Inc. reported a significant 216% net revenue growth to $431,609 in 2025, up from $136,643 in 2024, despite a net loss from continuing operations of $41.5 million, which included a large impairment charge. The pharmaceutical company plans to launch its second product, Rezenopy, in Q2 2026, building on the recent launch of Arbli and an overall strategic shift to a focused specialty pharmaceutical business.
2026-04-06 18:10:51
Scienture Holdings, Inc. provided its annual shareholder update, highlighting significant progress in 2025 including the acquisition of REZENOPY™ and FDA approval and commercial launch of Arbli™. The company detailed strong financial performance with increased revenue and gross margin, outlined strategic priorities for 2026 focusing on maximizing commercial performance, advancing its pipeline, and scaling infrastructure, while also addressing its Nasdaq compliance status.
2026-04-06 11:39:07
Scienture Holdings (SCNX) reported a 216% revenue increase in 2025 to $431,609, driven by the launch of Arbli. The company is preparing to launch REZENOPY, an opioid overdose nasal spray, in Q2 2026, having secured GPO agreements providing access to over 5,000 healthcare facilities. Despite a net loss due to a non-cash impairment, Scienture is focusing on commercialization and advancing its pipeline, while addressing Nasdaq's minimum bid price requirement.
2026-04-01 09:40:51
Scienture Holdings Inc (SCNX) is currently considered to be in the "Fair zone" based on its forward PS ratio of 0.67, which is comparable to its five-year average of 5.15. While its P/S ratio aligns with the industry average, the article notes that this premium may be unsustainable given robust revenue growth of -417.80%. The analysis also provides current P/B, FCF yield, Forward P/E, and Forward P/S ratios for SCNX as of April 1, 2026.
2026-03-30 15:38:58
Scienture Holdings Inc (MEDS) reported its FY2025 earnings with a basic and diluted EPS of -$2.70. The company's revenue reached $431,609, marking a significant 216.0% increase year-over-year. Despite the revenue growth, Scienture Holdings Inc recorded a net loss of $41.5 million for the year.
